Skip to main content

Table 3 Selected resistance findings from the ambulatory sector only of the most up-to-date grey literature included

From: Antibiotic resistance in primary care in Austria - a systematic review of scientific and grey literature

Location Pathogen Tested isolates Antibiotics Resistance in % Additional information
2009 and 2008 AURES [39, 61]Bundesministerium f. Gesundheit Österreich
   2008 2009   2008 2009 2008 2009
Respiratory tract S. pyogenes 977 1,440 PEN 0 0   
   1,436 1,433 macrolides 3.6 3.3   
   1,438 1,356 fluoroquinolones 0.7 0.3   
  S. pneumoniae 510 454 PEN 0.8 1.8   
   510 454 macrolides 14.5 13.4   
   506 455 fluoroquinolones 0.8 0.2   
  H. influenzae 1,244 1,255 AMP or AMX 9.4 9.6   
   1,244 1,255 AMC 0 0.1   
   1,244 1,234 fluoroquinolones 0.2 0   
All locations S. aureus 2,395 3,970 OXA 2.4 2.1 MRSA
2.4% 		MRSA
2.1%
   2,994 3,746 macrolides 14.5 14.9   
   3,045 3,757 CLI 6.9 9.7   
   3,277 3,547 SXT 0,8 0.6   
   1,633 3,886 fluoroquinolones 3.8 3.6   
Urinary tract E coli 8,992 11,218 AMP or AMX 39.8 43.9 ESBL
6.0% 		ESBL
6.4%
   8,985 11,219 AMC 5.8 9.2   
   9,088 11,107 cephalosporin 1st 8.5 9.7   
   8,992 11,225 SXT 24.6 27.5   
   8,992 11,241 fluoroquinolones 15.7 18.8   
   8,789 10,738 NIT 2.2 2.7   
   4,361 4,893 MEL 12.2 6.8   
   5,489 7,799 FOF 1.5 2.3   
  P.mirabilis n/a n/a      
Location Pathogen Tested isolates Antibiotics Resistance in % Additional information
2010 Medical University Graz, Department for Hygiene and Microbiology [70]
Respiratory tract S. pyogenes n/a      
  S. pneumoniae n/a      
  H. influenzae n/a      
  S. aureus 444 OXA 2.5 MRSA
2.5%
   441 SXT 0   
   434 CIP 3   
   444 ERY 14.9   
   444 CLI 13.7   
Urinary tract E. coli 3,907 AMX 61.4 ESBL
7.4%
   3,907 AMC 37.5   
   3,902 CFX 6.3   
   3,907 TMP 27.6   
   3,907 SXT 27.2   
   3,881 FOF 0.8   
   3,907 CIP 18.5   
   3,905 NIT 0.4   
2009 Laboratory Dr Richter and Dr Mustafa, Section for Microbiology, Salzburg [62]
Respiratory tract S. pyogenes n/a      
  S. pneumoniae n/a      
  H. influenzae n/a      
Skin and soft tissue S. aureus 938 OXA 3 MRSA
3%
   938 AMC 3   
   938 CFX 3   
   938 ERY 13   
   938 CLIN 3   
   938 SXT 1   
   938 MXF 3   
Urinary tract E. coli 2,506 AMP 40 ESBL
4%
   2,506 AMC 6   
   2,506 CFX 6   
   2,506 SXT 26   
   2,499 NIT 1   
   2,506 CIP 16   
   2,504 FOF 1   
  P. mirabilis n/a      
2009 Medical University Innsbruck, Section for Hygiene and Medical Microbiology [78]
Respiratory tract S. pyogenes 187 PEN 0   
   187 AZM 5.8   
   187 MXF 2.1   
  S. pneumoniae 115 PEN 0   
   115 AZM 12.1   
   115 MXF 0.87   
  H. influenzae 76 AMP 25   
   76 AMC 0   
   76 MXF 0   
All locations S. aureus 676 FOX 1.48 MRSA
6%
   610 AZM 20.9   
   610 CLIN 18   
   674 SXT 1.03   
   609 MXF 1.97   
Urinary tract E. coli 3,112 AMP 58 ESBL
9%
   3,104 AMC 20   
   3,101 CFZ 17   
   3,112 SXT 33   
   3,112 CIP 26   
   3,097 MEC 7   
   3,111 NIT 7   
2009 County Hospital Leoben, Bacteriological Laboratory [73]     
Respiratory tract S. pyogenes n/a      
  S. pneumoniae n/a      
  H. influenzae n/a      
  S. aureus 141 AMC 1.4   
   141 OXA 1.4   
   141 CFZ 1.4   
   140 CLIN 11.4   
   140 ERY 12.1   
   140 CIP 0.7   
Urinary tract E. coli 310 AMP 41   
   310 AMC 10   
   310 CFZ 10.0   
   309 TMP 29.5   
   310 CIP 20,0   
   309 NIT 1.9   
   27 MEC 11.1   
  P. mirabilis 28 AMC 10.7   
   28 CFZ 17.9   
   28 TMP 53.6   
   28 CIP 17.9   
Hell [80]         
Urinary tract E. coli
ESBL-producing 		100 MEC 11   
   100 FOF 3   
   100 NIT 1   
   100 SXT 73   
   100 CIP 78   
  1. Abbr.: FOF, fosfomycin; MEL, pivmecillinam; NIT, nitrofurantoin; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; PEN, penicillin; ERY, erythromycin; CLI, clindamycin; AMP, ampicillin; AMX, amoxicillin; AMC, amoxicillin/clavulanate; MEC, mecillinam; TMP, trimethoprim; SUL, sulfamethoxazole; AZM, azithromycin; CFZ, cefazolin; FOX, cefoxitin; OXA, oxacillin; MXF, moxifloxacin
  2. n/a: Resistance data of isolates from primary care alone not available
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us